BRÈVE

sur NeuroSync Laboratories

NeuroSync Labs revolutionizes the VR experience with a solution for motion sickness

Galveston, Texas-based NeuroSync Labs recently announced the publication of its innovative research on reducing motion sickness in virtual reality (VR) by the prestigious journal Neuroscience Letters. This study presents a significant advance with the C-Infinity, a full-body gaming controller, by demonstrating a significant reduction in nausea in users of META Quest 2 headsets.

The C-Infinity, which has just had a successful launch on Kickstarter, allows for a more immersive and comfortable VR gaming experience, while reducing motion sickness. This controller promotes greater immersion and extends VR usage time, helping to make VR more accessible and inclusive.

Dr. Slobodan Paessler, co-founder of NeuroSync Laboratories, notes that VR has the potential to transform areas far beyond gaming, such as treating depression, supporting post-traumatic recovery, and improving accessibility for physically disabled people.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de NeuroSync Laboratories